Cargando…
SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA
People with type 2 diabetes (T2D) with concomitant chronic kidney disease (CKD) and cardiovascular (CV) disease are at increased risk for recurrent CV events and hypoglycemia. Treatment of these individuals is clinically challenging, where the evidence-base for safety and efficacy of glucose lowerin...
Autores principales: | Kahn, Steven, Perkovic, Vlado, Johansen, Odd Erik, Rosenstock, Julio, McGuire, Darren, Toto, Robert, Nikolaus, Marx, Alexander, John, Zinman, Bernard, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis, von Eynatten, Max, Cooper, Mark, Wanner, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553362/ http://dx.doi.org/10.1210/js.2019-SUN-LB015 |
Ejemplares similares
-
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
por: Perkovic, Vlado, et al.
Publicado: (2020) -
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021) -
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021) -
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA(®)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
por: Rosenstock, Julio, et al.
Publicado: (2018) -
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial
por: Cooper, Mark E., et al.
Publicado: (2020)